Afya Limited
AFYA · NASDAQ Global Select · USD
10,71USD
+0,21 (+2,04 %)Stand 9. Nov., 18:36
Kennzahlen
- Eröffnung
- 10,51
- Vortag
- 10,50
- Tagesspanne
- 10,48 – 10,80
- 52 Wochen
- 9,66 – 16,16
- Volumen
- 51.778,1
- Ø Volumen
- 310.500
- Börsenwert
- 979,86 Mio. $
- KGV
- 6,8
- Gewinn je Aktie (TTM)
- 8,68
- Dividendenrendite
- 6,1 %
- Beta
- 0,4
- Nächste Zahlen
- 12. Nov. 2026
Finanzen
| BRL | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 3,62 Mrd. | 3,3 Mrd. | 2,88 Mrd. | 2,33 Mrd. | 1,72 Mrd. |
| Herstellungskosten | 1,29 Mrd. | 1,22 Mrd. | 1,11 Mrd. | 859,55 Mio. | 652,3 Mio. |
| Bruttogewinn | 2,34 Mrd. | 2,09 Mrd. | 1,77 Mrd. | 1,47 Mrd. | 1,07 Mrd. |
| Forschung und Entwicklung | 0 | 20,09 Mio. | 21,5 Mio. | 9,44 Mio. | 0 |
| Vertrieb und Verwaltung | 1,15 Mrd. | 1,07 Mrd. | 1,01 Mrd. | 798,15 Mio. | 622,62 Mio. |
| Operatives Ergebnis | 1,19 Mrd. | 1,01 Mrd. | 767,06 Mio. | 664,1 Mio. | 440,9 Mio. |
| EBITDA | 1,34 Mrd. | 1,35 Mrd. | 1,11 Mrd. | 923,31 Mio. | 603,33 Mio. |
| Nettogewinn | 737,68 Mio. | 631,51 Mio. | 386,32 Mio. | 373,57 Mio. | 223,33 Mio. |
| Gewinn je Aktie (verwässert) | 8,11 | 6,93 | 4,27 | 4,15 | 2,37 |
Bewertung
Letzte 12 Monate
- KGV
- 6,8
- Kurs-Umsatz-Verhältnis
- 1,4
- Kurs-Buchwert-Verhältnis
- 1,1
- PEG
- 0,5
- Bruttomarge
- 64,0 %
- Operative Marge
- 32,2 %
- Nettomarge
- 20,4 %
- Verschuldungsgrad
- 0,6
- EV/EBITDA
- 4,6
- Eigenkapitalrendite
- 16,4 %
- Kapitalrendite (ROIC)
- 12,9 %
- Free-Cashflow-Rendite
- 21,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 64,5 % | 63,2 % | 61,4 % | 63,1 % | 62,1 % |
| Operative Marge | 32,8 % | 30,6 % | 26,7 % | 28,5 % | 25,6 % |
| Nettomarge | 20,4 % | 19,1 % | 13,4 % | 16,0 % | 13,0 % |
| KGV | 10,3 | 14,0 | 24,9 | 19,9 | 36,6 |
| Kurs-Umsatz-Verhältnis | 2,1 | 2,7 | 3,3 | 3,2 | 4,7 |
| Kurs-Buchwert-Verhältnis | 1,6 | 2,1 | 2,7 | 2,3 | 2,8 |
| Verschuldungsgrad | 0,6 | 0,7 | 0,7 | 0,8 | 0,7 |
| Liquidität 3. Grades | 2,2 | 1,4 | 1,1 | 1,8 | 1,6 |
| Dividendenrendite | 1,5 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 9,63 Mrd. | 11,13 Mrd. | 11,75 Mrd. | 9,04 Mrd. | 9,57 Mrd. |
| EV/EBITDA | 7,2 | 8,3 | 10,6 | 9,8 | 15,9 |
| Eigenkapitalrendite | 15,2 % | 14,8 % | 10,7 % | 11,7 % | 7,6 % |
| Kapitalrendite (ROIC) | 12,4 % | 12,0 % | 10,7 % | 9,3 % | 6,7 % |
| Free-Cashflow-Rendite | 13,6 % | 11,7 % | 8,3 % | 7,4 % | 4,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +9,7 % | +14,9 % | +23,5 % | +35,5 % | +43,1 % |
| Bruttogewinn | +11,9 % | +18,3 % | +20,2 % | +37,7 % | +39,2 % |
| Operatives Ergebnis | +17,5 % | +31,9 % | +15,5 % | +50,6 % | +21,3 % |
| Nettogewinn | +16,8 % | +63,5 % | +3,4 % | +67,3 % | −23,5 % |
| Gewinn je Aktie | +17,0 % | +62,3 % | +2,9 % | +75,1 % | −24,0 % |
| Freier Cashflow | −0,3 % | +30,3 % | +46,0 % | +54,5 % | +51,4 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 5Kaufen
- 2Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
14,80
Durchschnitt · +38,13 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 3,75 Mrd. | 3,99 Mrd. | 4,19 Mrd. |
| Umsatz (Tief – Hoch) | 3,74 Mrd. – 3,76 Mrd. | 3,95 Mrd. – 4,04 Mrd. | 4,1 Mrd. – 4,36 Mrd. |
| Gewinn je Aktie (Ø) | 8,64 | 9,35 | 9,23 |
| Gewinn je Aktie (Tief – Hoch) | 2,85 – 14,44 | 3,01 – 15,68 | 7,35 – 10,80 |
| Analysten | 4 | 4 | 3 |
Letzte Änderungen
- JP Morgan3. Nov. 2026Overweight
- Citigroup3. Nov. 2026Neutral → Buy
- JP Morgan7. Okt. 2026Neutral → Overweight
- JP Morgan22. Juni 2026Neutral
- JP Morgan30. Apr. 2026Neutral
- B of A Securities24. Feb. 2026Buy → Neutral
- Morgan Stanley13. Feb. 2026Equal Weight → Underweight
- UBS16. Jan. 2026Buy → Neutral
Quartalszahlen
Nächste Zahlen: 12. Nov. 2026| Aug. 2026 | Mai 2026 | März 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | März 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,39 | 0,53 | 0,38 | 0,32 | 0,40 | 0,46 | 0,34 | 0,36 |
| Gewinn je Aktie · Tatsächlich | 0,45 | 0,56 | 0,41 | 0,38 | 0,40 | 0,55 | 0,36 | 0,32 |
| Abweichung | +15,71 % | +5,66 % | +7,89 % | +18,75 % | 0,00 % | +19,57 % | +5,88 % | −11,11 % |
| Umsatz · Tatsächlich | 187,42 Mio. | 192,67 Mio. | 166,26 Mio. | 174,05 Mio. | 169,26 Mio. | 160,33 Mio. | 136,95 Mio. | 153,95 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 25. März 2026 | 6. Apr. 2026 | 0,66 |
| 26. März 2025 | 4. Apr. 2025 | 0,23 |
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 12,22 %
- Investoren mit 13F-Meldung
- 55
Größte Investoren
- FMR LLC2,94 %2,61 Mio.
- SOFTBANK GROUP CORP.2,74 %2,43 Mio.
- DOMA PERPETUAL CAPITAL MANAGEMENT LLC2,70 %2,4 Mio.
- BAMCO INC /NY/1,32 %1,18 Mio.
- RENAISSANCE TECHNOLOGIES LLC0,39 %343.300
- BLACKROCK, INC.0,36 %323.785
- SWEDBANK AB0,21 %189.200
- TWO SIGMA INVESTMENTS, LP0,18 %155.712
Insider-Geschäfte
- FERREIRA SANTOS WELDER5. Okt. 2026 · officer: ControllerVerkauf4161 Aktien · 13,30
- Junior Lelio de Souza1. Juli 2026 · officer: Vice PresidentVerkauf36.204 Aktien · 15,00
- Basolli Gomiero Mirella26. Juni 2026 · officer: Vice PresidentVerkauf10.000 Aktien · 14,80
- Junior Lelio de Souza26. Juni 2026 · officer: Vice PresidentVerkauf41.541 Aktien · 15,00
- Gibbon Virgilio Deloy Capobianco7. Mai 2026 · officer: Chief Executive OfficerKauf59.000 Aktien
- Gibbon Virgilio Deloy Capobianco7. Mai 2026 · officer: Chief Executive OfficerVerkauf16.225 Aktien · 14,41
- Gibbon Virgilio Deloy Capobianco7. Mai 2026 · officer: Chief Executive OfficerVerkauf9000 Aktien
- Gibbon Virgilio Deloy Capobianco7. Mai 2026 · officer: Chief Executive OfficerVerkauf32.000 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical schools, preparatory courses for medical residency, advanced graduate studies, and various other programs tailored for medical professionals at all career stages. These offerings are available across its proprietary network and are also extended to external medical institutions. Beyond traditional education, Afya also offers digital health services through a subscription-based platform, accessible via a mobile app and website. This platform is specifically designed to assist healthcare practitioners and students with clinical decision-making by providing essential tools such as medical calculators, reference charts, up-to-date content, prescription guidance, clinical scoring systems, details on medical procedures, and laboratory examination information. While strong in medicine, Afya's educational portfolio spans a broader spectrum of health sciences, including dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine. Furthermore, the company extends its academic offerings beyond healthcare to include undergraduate and postgraduate degree programs in diverse subjects like business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. The company further enhances its educational ecosystem by providing specialized postgraduate medical programs, both printed and digital educational materials, an online medical learning platform, and hands-on medical training opportunities. As of December 31, 2021, Afya maintained an extensive network of 46 undergraduate and graduate medical school campuses, which included 30 operational undergraduate units and five approved units. This infrastructure supported a total capacity of 2,731 medical school seats, with 2,481 actively operating and an additional 278 seats approved for future use. Established in 1999, Afya Limited is headquartered in Nova Lima, Brazil.
Führung
- Julio Eduardo Razente de AngeliVice President of Continuing Education & Innovation
- Virgílio Deloy Capobianco GibbonChief Executive Officer
- Renata CoutoInvestor Relations Executive Manager
- Luis Andre Carpintero BlancoChief Financial Officer
- CEO
- Virgilio Deloy Capobianco Gibbon
- Mitarbeitende
- 9.395
- Hauptsitz
- Belo Horizonte, MG, BR
- Sektor
- Consumer Defensive
- Branche
- Education & Training Services
- Börsengang
- 19. Juli 2019
- Website
- institucional.afya.com.br
Nachrichten
- Zacks Investment Research · 4. Nov., 11:01Afya (AFYA) Earnings Expected to Grow: Should You Buy?
- Defense World · 27. Okt., 4:19Afya (NASDAQ:AFYA) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened
- MarketBeat · 23. Okt., 4:02Afya Maps Yduqs Merger, BRL 2.2B Synergies and Digital Health Growth at Investor Day
- Seeking Alpha · 20. Okt., 18:43Afya Limited (AFYA) Analyst/Investor Day Transcript
- Zacks Investment Research · 7. Okt., 12:40AFYA or UTI: Which Is the Better Value Stock Right Now?
- Zacks Investment Research · 7. Okt., 10:41Should Value Investors Buy Afya (AFYA) Stock?
- GuruFocus · 6. Okt., 20:12Is It Too Late to Buy Afya Ltd (AFYA) After 4.5% Rally? GF Value Says Undervalued
- Business Wire · 1. Okt., 18:53Afya Limited and YDUQS Participações S.A. Controlling Shareholders Enter Into Voting Commitment Agreement
- Business Wire · 1. Okt., 18:53Merger Agreement and Other Covenants Entered Into by and Between AFYA LIMITED and YDUQS PARTICIPAÇÕES S.A.
- Business Wire · 1. Okt., 17:21Afya Limited to Host Afya Day 2026 on October 20th in Rio de Janeiro
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.